Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
GSK has scored a hit with early results from a pivotal study of its PD-L1 inhibitor cancer therapy Jemperli, showing the drug significantly extended progression-free survival, the primary endpoint, when added to standard-of-care chemotherapy in patients with with primary advanced or recurrent endometrial cancer.
The company believes the interim results from the Phase III RUBY study show that Jemperli (dostarlimab) can “redefine” treatment of...
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Multi-blockbuster falls short in a giant cell arteritis study.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
Multi-blockbuster falls short in a giant cell arteritis study.
Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.
